Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

169 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate delayed-release capsules will result in improvement in liver disease severity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fatty Liver Disease in Obese Children

NCT02117700

Obesity Nonalcoholic Fatty Liver Disease Cardiovascular Disease

COMPLETED PHASE1/PHASE2

Gemcabene for the Treatment of Pediatric NAFLD

NCT03436420

Non-Alcoholic Fatty Liver Disease

TERMINATED PHASE2

A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity

NCT02787668

Non-alcoholic Fatty Liver Disease Childhood Obesity Insulin Resistance

COMPLETED NA

GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis

NCT01589523

Bile Acid Synthesis Defect Inborn Error of Bile Acid Metabolism Inborn Error of Bile Acid Conjugation

COMPLETED PHASE3

Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis

NCT00004368

Cirrhosis Liver Cirrhosis

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonalcoholic Fatty Liver Disease (NAFLD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DR cysteamine bitartrate capsule

Active DR cysteamine bitartrate capsule

Group Type ACTIVE_COMPARATOR

DR cysteamine bitartrate capsule

Intervention Type DRUG

* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline
* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline

DR cysteamine bitartrate placebo

Placebo DR cysteamine bitartrate capsule

Group Type PLACEBO_COMPARATOR

DR cysteamine bitartrate placebo

Intervention Type OTHER

* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline
* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DR cysteamine bitartrate capsule

* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline
* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline

Intervention Type DRUG

DR cysteamine bitartrate placebo

* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline
* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cysteamine bitartrate delayed-release

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children age 8-17 years
* Liver biopsy obtained within 90 days of screening visit and not more than 120 days before randomization
* Clinical history consistent with nonalcoholic fatty liver disease (NAFLD)
* Definite NAFLD based upon liver histology
* No evidence of any other liver disease by clinical history or histological evaluation
* A histological severity of: NAFLD Activity Score (NAS) ≥ 4.
* Sexually active female participants of childbearing potential (i.e., not surgically sterile \[defined as tubal ligation, hysterectomy, or bilateral oophorectomy\]) must agree to utilize the same two acceptable forms of contraception from screening through completion of the study and to complete a serum pregnancy test at each study visit. The acceptable forms of contraception for this study include hormonal contraceptives (oral, implant, transdermal patch, or injection) at a stable dose for at least 3 months prior to screening, and barrier (condom with spermicide, diaphragm with spermicide). Sexual activity will be ascertained at each study visit for post-menarchal females and if sexually active, subject must verify use of the same 2 acceptable forms of contraception. For pre-pubescent children, a documented attestation of abstinence from their parent or guardian will be acceptable.
* Participants must be able to swallow DR Cysteamine tablets with the tablet intact
* Written informed consent from parent or legal guardian
* Written informed assent from the child

Exclusion Criteria

* Participants with a current history of the following conditions or any other health issues that make it unsafe for them to participate in the opinion of the Investigators:

* Inflammatory bowel disease (if currently active) or prior resection of small intestine
* Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias)
* Seizure disorder
* Active coagulopathy
* Gastrointestinal ulcers/bleeding
* Renal dysfunction with a creatinine clearance \< 90 mL/min/m2
* History of active malignant disease requiring chemotherapy within the past 12 months prior to randomization
* History of significant alcohol intake (AUDIT questionnaire) or inability to quantify alcohol consumption
* Chronic use (more than 2 consecutive weeks) of medications known to cause hepatic steatosis or steatohepatitis (systemic glucocorticoids, tetracycline, anabolic steroids, valproic acid, salicylates, tamoxifen) in the past year.
* The use of other known hepatotoxins within 90 days of liver biopsy or within 120 days of randomization
* Initiation of medications with the intent to treat NAFLD/NASH in the time period following liver biopsy and prior to randomization
* History of total parenteral nutrition (TPN) use in year prior to screening
* History of bariatric surgery or planning to undergo bariatric surgery during study duration
* Clinically significant depression (patients hospitalized for suicidal ideations or suicide attempts within the past 12 months)
* Any female nursing, planning a pregnancy, known or suspected to be pregnant, or who has a positive serum pregnancy screen.
* Non-compensated liver disease with any one of the following hematologic, biochemical, and serological criteria on entry into protocol:

* Hemoglobin \< 10 g/dL;
* White blood cell (WBC) \< 3,500 cells/mm3 of blood;
* Neutrophil count \< 1,500 cells/mm3 of blood;
* Platelets \< 130,000 cells/mm3 of blood;
* Direct bilirubin \> 1.0 mg/dL
* Total bilirubin \>3 mg/dL
* Albumin \< 3.2 g/dL
* International normalized ratio (INR) \> 1.4
* Poorly controlled diabetes mellitus (hemoglobin A1c (HbA1c) \> 9%)
* Evidence of other chronic liver disease:

* Biopsy consistent with histological evidence of autoimmune hepatitis
* Serum hepatitis B surface antigen (HBsAg) positive.
* Serum hepatitis C antibody (anti-HCV) positive.
* Iron/total iron binding capacity (TIBC) ratio (transferrin saturation) \> 45% with histological evidence of iron overload
* Alpha-1-antitrypsin (A1AT) phenotype ZZ or SZ
* Wilson's disease
* Children who are currently enrolled in a clinical trial or who received an investigational study drug within 180 days of screening or liver biopsy.
* Subjects who are not able or willing to comply with the protocol or have any other condition that would impede compliance or hinder completion of the study, in the opinion of the investigator.
* Failure to give informed consent

Minimum Eligible Age

8 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No